As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority. Our R&D community is made up of scientists, physicians, technicians, product and manufacturing engineers and world-class innovators, all of whom contribute to our scientific leadership. Our goal is breakthrough innovation that can transform, extend and potentially save lives.
As of 30 September 2021, the drugs and vaccines in Sanofi's R&D pipeline include 82 projects, 34 of which are in phase 3 or have been submitted to regulatory authorities for approval. These projects represent new molecular entities as well as existing therapeutics being investigated for additional indications, or different formulations.
Sanofi is investing in these research areas to find innovative solutions for patients:
Sanofi researchers aim to rebalance immune and inflammatory responses that drive systemic, chronic diseases. By combining molecular, clinical, and real-world data, our R&D teams are gaining new ground in precision immunology. They apply deep knowledge of disease and an array of technologies to investigate common pathways in systemic diseases (e.g. asthma, atopic dermatitis) and peripheral inflammatory diseases (e.g. rheumatoid arthritis), as well as autoimmune challenges in type 1 diabetes and cancer.
With clear focus, deep internal expertise, and industry-leading partners, our scientists are designing new and potentially life-transforming medicines for cancer patients worldwide. Our teams combine extensive heritage in small-molecule research with advanced biologic capabilities to move cancer therapy forward. Our oncology strategy includes a focus on four disease areas: multiple myeloma and other blood cancers, skin cancers, lung cancers, and breast cancer and other hormone-positive cancers.
Sanofi R&D teams aim to transform the standard of care for people who are affected by rare blood disorders. The company's unique R&D program builds on a legacy of innovation, stemming from the development of the first extended half-life clotting factors for treating hemophilia A and B, branching out to the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), and cutting-edge research in cold agglutinin disease.
Sanofi has a strong foundation in lysosomal storage disorders: a group of rare, genetic conditions caused by enzyme deficiencies. Our teams are developing pioneering medicines for disorders such as Fabry, Gaucher, and Pompe diseases, and advancing toward new treatments for patients with GM2 gangliosidoses (Tay-Sachs disease, AB variant, and Sandhoff disease) and acid sphingomyelinase deficiency (ASMD). The insights we gain from research into rare diseases can have applications for other diseases.
Sanofi Pasteur is at the forefront of vaccine research and development, creating immunological solutions to prevent and cure diseases for every stage of life. We continuously harness new scientific knowledge and technologies to design safe and effective vaccines against complex diseases. Innovation is key to improving people's health around the world and to the company's success. That's why we devote more than €1 million to research and development every day. Our goal is to turn scientific breakthroughs and personal health insights into protective vaccines for people and communities around the world.
Next Generation Approaches to Pioneer Breakthrough Therapies
At Sanofi, we are developing medicines that have the potential to help transform patients’ lives by using the most advanced technology platforms to pioneer new innovative approaches to tackle diseases.